Hillsdale Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Hillsdale Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Sell	1,030 -510	-33%	-$120K	0.01%	524
2026 Q1	$307K	Buy	1,540 +1,500	+3,750%	+$297K	0.01%	504
2025 Q4	$7.56K	Buy	+40	New	+$7.69K	﹤0.01%	620
2024 Q2	–	Sell	-45,032	Closed	-$3.29M	–	645
2024 Q1	$3.29M	Buy	45,032 +3,500	+8%	+$258K	0.26%	156
2023 Q4	$2.97M	Sell	41,532 -6,100	-13%	-$360K	0.24%	157
2023 Q3	$2.85M	Sell	47,632 -6,100	-11%	-$401K	0.26%	144
2023 Q2	$3.87M	Buy	+53,732	New	+$4.03M	0.36%	120

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hillsdale Investment Management's LGND Position: Q2 2026 in Review

Hillsdale Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 33% in Q2 2026, selling an estimated $120K and leaving 1,030 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #524.

Hillsdale Investment Management first reported a position in LGND in Q2 2023 and has held it in 7 quarters since. The position peaked at $3.87M in Q2 2023. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Hillsdale Investment Management held 1,030 shares of Ligand Pharmaceuticals worth $326K as of Q2 2026.
Hillsdale Investment Management sold 510 Ligand Pharmaceuticals shares in Q2 2026, an estimated $120K.
Ligand Pharmaceuticals made up 0.01% of Hillsdale Investment Management's portfolio in Q2 2026, its #524 holding.
Hillsdale Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Hillsdale Investment Management's Ligand Pharmaceuticals position peaked at $3.87M in Q2 2023.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.